Media Center
Press Releases

Press Releases

20 Mar 17
Asia-Pacific non-small cell lung cancer market to soar to $6.2 billion by 2023, says GBI Research

The non-small cell lung cancer (NSCLC) market in the Asia-Pacific (APAC) region will more than double from $3 billion in 2016 to $6.2 billion by 2023, representing a substantial compound annual growth rate of 10.8%, according to business intelligence provider GBI Research.

Read post
16 Mar 17
As fatty liver disease prevalence soars, pharma companies look to first-in-class drugs, says GBI Research

Due to the increasing global prevalence of fatty liver disease (FLD), which comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), potentially leading to inflammation (steatohepatitis) and fibrosis, pharmaceutical companies are looking to first-in-class treatments to help to address increasingly urgent unmet needs, according to business intelligence provider GBI Research.

Read post
14 Mar 17
Global cancer supportive care therapeutics market to see negligible growth to $12.4 billion by 2022, says GBI Research

The global cancer supportive care market, which covers chemotherapy-induced neutropenia, chemotherapy-induced anemia, chemotherapy-induced nausea and vomiting, cancer pain, bone metastasis, and oral mucositis, is set to experience a low level of growth from $11.7 billion in 2015 to $12.4 billion by 2022, at a compound annual growth rate of 0.9%, according to business intelligence provider GBI Research.

Read post
13 Mar 17
$100 billion of revenues up for grabs for drug manufacturers by 2020 as patents for key biologics expire, says GBI Research

Although complexities inherent in biological drug manufacturing are creating barriers for further expansion of the biosimilars market, imminent patent expiries of key biologics are set to create new opportunities for biosimilar manufacturers, according to business intelligence provider GBI Research.

Read post
09 Mar 17
Global respiratory complications market to exceed $30 billion by 2022, despite limited pipeline, says GBI Research

The respiratory complications market is set to grow from $21.8 billion in 2015 to $30.2 billion by 2022, representing a compound annual growth rate of 4.7%, according to business intelligence provider GBI Research.

Read post